Christoph Winkler

Dr. Christoph Winkler


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2021 in ACS Central Science
Verified
Journal Article
Closed access
CWChristoph Winkler
Christoph Winkler
JSJoerg Schrittwieser
Joerg Schrittwieser
WKWolfgang Kroutil
Wolfgang Kroutil

9 April 2019 in ACS Catalysis
Verified
Journal Article
Open access
LSLuca Schmermund
Luca Schmermund
VJValentina Jurkaš
Valentina Jurkaš
FÖF. Feyza Özgen
F. Feyza Özgen
GBGiovanni Davide Barone
Giovanni Davide Barone
HBHanna C. Büchsenschütz
Hanna C. Büchsenschütz
WKWolfgang Kroutil
Wolfgang Kroutil
Light has received increased attention for various chemical reactions but also in combination with biocatalytic reactions. Because currently only a few enzymatic reactions are known, which per se require light, most transformations involving light and a biocatalyst exploit light either for providing the cosubstrate or cofactor in an appropriate redox state for the biotransformation. In selected cases, a promiscuous activity of known enzymes in the presence of light could be induced. In other approaches, light-induced chemical reactions have been combined with a biocatalytic step, or light-induced biocatalytic reactions were combined with chemical reactions in a linear cascade. Finally, enzymes with a light switchable moiety have been investigated to turn off/on or tune the actual reaction. This Review gives an overview of the various approaches for using light in biocatalysis.

24 January 2023 in Chemical Reviews
Verified
Journal Article
Open access
SBSarah Bierbaumer
Sarah Bierbaumer
MNMaren Nattermann
Maren Nattermann
LSLuca Schulz
Luca Schulz
RZReinhard Zschoche
Reinhard Zschoche
TETobias Erb
Tobias Erb
SGSilvia M. Glueck
Silvia M. Glueck

30 November 2021 in Chemical Reviews
Verified
Journal Article
Open access
SSStefan Simić
Stefan Simić
EZErna Zukić
Erna Zukić
LSLuca Schmermund
Luca Schmermund
KFKurt Faber
Kurt Faber
CWChristoph Winkler
Christoph Winkler
WKWolfgang Kroutil
Wolfgang Kroutil
Biocatalysis, using enzymes for organic synthesis, has emerged as powerful tool for the synthesis of active pharmaceutical ingredients (APIs). The first industrial biocatalytic processes launched in the first half of the last century exploited whole-cell microorganisms where the specific enzyme at work was not known. In the meantime, novel molecular biology methods, such as efficient gene sequencing and synthesis, triggered breakthroughs in directed evolution for the rapid development of process-stable enzymes with broad substrate scope and good selectivities tailored for specific substrates. To date, enzymes are employed to enable shorter, more efficient, and more sustainable alternative routes toward (established) small molecule APIs, and are additionally used to perform standard reactions in API synthesis more efficiently. Herein, large-scale synthetic routes containing biocatalytic key steps toward >130 APIs of approved drugs and drug candidates are compared with the corresponding chemical protocols (if available) regarding the steps, reaction conditions, and scale. The review is structured according to the functional group formed in the reaction.

1 May 2020 in Biotechnology Advances
Verified
Journal Article
Open access
BWBirgit Wiltschi
Birgit Wiltschi
Tomislav CernavaTomislav Cernava
Tomislav Cernava
ADAlexander Dennig
Alexander Dennig
MCMeritxell Galindo Casas
Meritxell Galindo Casas
MGMartina Geier
Martina Geier
TWTamara Wriessnegger
Tamara Wriessnegger
Competitive sustainable production in industry demands new and better biocatalysts, optimized bioprocesses and cost-effective product recovery. Our review sheds light on the progress made for the individual steps towards these goals, starting with the discovery of new enzymes and their corresponding genes. The enzymes are subsequently engineered to improve their performance, combined in reaction cascades to expand the reaction scope and integrated in whole cells to provide an optimal environment for the bioconversion. Strain engineering using synthetic biology methods tunes the host for production, reaction design optimizes the reaction conditions and downstream processing ensures the efficient recovery of commercially viable products. Selected examples illustrate how modified enzymes can revolutionize future-oriented applications ranging from the bioproduction of bulk-, specialty- and fine chemicals, active pharmaceutical ingredients and carbohydrates, over the conversion of the greenhouse-gas CO2 into valuable products and biocontrol in agriculture, to recycling of synthetic polymers and recovery of precious metals.

1 December 2012 in Journal of Biotechnology
Verified
Journal Article
Open access
CWChristoph Winkler
Christoph Winkler
GTGábor Tasnádi
Gábor Tasnádi
DCDorina Clay
Dorina Clay
MHMélanie Hall
Mélanie Hall
KFKurt Faber
Kurt Faber
Ene-reductases from the 'Old Yellow Enzyme' family of flavoproteins catalyze the asymmetric reduction of various α,β-unsaturated compounds at the expense of a nicotinamide cofactor. They have been applied to the synthesis of valuable enantiopure products, including chiral building blocks with broad industrial applications, terpenoids, amino acid derivatives and fragrances. The combination of these highly stereoselective biocatalysts with a cofactor recycling system has allowed the development of cost-effective methods for the generation of optically active molecules, which is strengthened by the availability of stereo-complementary enzyme homologues.